Cuncai Zhou

Nanchang, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Development and external validation of a novel online calculator for predicting long-term survival following radical hepatectomy in patients with BCLC stage 0/A hepatocellular carcinoma and clinically significant portal hypertension.

Development and external validation of a novel online calculator for predicting long-term survival following radical hepatectomy in patients with BCLC stage 0/A hepatocellular carcinoma and clinically significant portal hypertension.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: October 07, 2025

Chinese multicenter expert consensus on the diagnosis and treatment of hilar cholangiocarcinoma: 2025 edition.

Chinese multicenter expert consensus on the diagnosis and treatment of hilar cholangiocarcinoma: 2025 edition.

Journal: Bioscience trends
Published: August 13, 2025

Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006).

Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006).

Journal: Nature communications
Published: April 30, 2025

Synchronous hepatectomy and splenectomy for patients with BCLC stage 0/A hepatocellular carcinoma and clinically significant portal hypertension: A multicenter retrospective cohort study.

Synchronous hepatectomy and splenectomy for patients with BCLC stage 0/A hepatocellular carcinoma and clinically significant portal hypertension: A multicenter retrospective cohort study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: April 14, 2025

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).

Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition).

Journal: Liver cancer
Published: January 18, 2022

Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition).

Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition).

Journal: Liver cancer
Published: December 03, 2021

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Journal: The lancet. Gastroenterology & hepatology
Published: January 28, 2021

Identification of key miRNAs in the progression of hepatocellular carcinoma using an integrated bioinformatics approach.

Identification of key miRNAs in the progression of hepatocellular carcinoma using an integrated bioinformatics approach.

Journal: PeerJ
Published: October 16, 2019

c[RGDyk]-coated liposomes loaded with adriamycin and miR-21 mimics inhibit the growth of hepatoma cell line SMCC-7721 via up-regulating Bax and p53.

c[RGDyk]-coated liposomes loaded with adriamycin and miR-21 mimics inhibit the growth of hepatoma cell line SMCC-7721 via up-regulating Bax and p53.

Journal: Translational cancer research
Published: February 21, 2019

Up-regulated microRNA-33b inhibits epithelial-mesenchymal transition in gallbladder cancer through down-regulating CROCC.

Up-regulated microRNA-33b inhibits epithelial-mesenchymal transition in gallbladder cancer through down-regulating CROCC.

Journal: Bioscience reports
Published: January 11, 2019

MicroRNA-1305 Inhibits the Stemness of LCSCs and Tumorigenesis by Repressing the UBE2T-Dependent Akt-Signaling Pathway.

MicroRNA-1305 Inhibits the Stemness of LCSCs and Tumorigenesis by Repressing the UBE2T-Dependent Akt-Signaling Pathway.

Journal: Molecular therapy. Nucleic acids
Published: December 12, 2018

miR‑21 inhibitor facilitates the anticancer activity of doxorubicin loaded nanometer in melanoma.

miR‑21 inhibitor facilitates the anticancer activity of doxorubicin loaded nanometer in melanoma.

Journal: Oncology reports
Published: June 05, 2018
Showing 1-12 of 13

Last Updated: 09/26/2026